Pasithea Therapeutics to present initial PAS-004 Phase 1/1b data
Pasithea Therapeutics says it will present initial PAS-004 clinical data from its ongoing Phase 1/1b trial in adult NF1 patients at the 2026 European Neurofibromatosis Conference.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.